727 filings
Page 9 of 37
425
j46z pfrmehxcsa
1 Dec 22
Business combination disclosure
4:04pm
8-K
3vklg0adases0co
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
425
0obwb6c66a3kfd6nmc
29 Nov 22
Business combination disclosure
4:03pm
8-K
qc9mn0ng
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
91m21qcuk
28 Nov 22
Business combination disclosure
4:03pm
8-K
zrok8dv
28 Nov 22
Regulation FD Disclosure
4:01pm
SEC STAFF
2a7 y4rrpnd7
17 Nov 22
SEC staff action: Order
12:00am
425
r95r ra0eyo3
15 Nov 22
Business combination disclosure
4:03pm
8-K
47c8g
15 Nov 22
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
4:02pm
425
4q9mtrbx95
14 Nov 22
Business combination disclosure
8:50am
8-K
k9qk9 gjbfz3
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
EFFECT
80z1u8k
14 Nov 22
Notice of effectiveness
12:15am
424B3
67oyu6hghc245uuw
10 Nov 22
Prospectus supplement
4:21pm
CORRESP
2xm gm0336k83c
8 Nov 22
Correspondence with SEC
12:00am
CORRESP
f000ia5ya ieitg
4 Nov 22
Correspondence with SEC
12:00am
UPLOAD
myy2s4w6 8aw969
1 Nov 22
Letter from SEC
12:00am
425
znj1txxm
27 Oct 22
Business combination disclosure
7:15am
8-K
sla2sarq4w
27 Oct 22
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
7:13am